DARA Biosciences Inc (NASDAQ:DARA) on May 15 announced its support for Neuropathy Awareness Week which is being observed during the week of May 12, 2014 and sponsored in the U.S. by The Neuropathy Association (www.neuropathy.org). DARA Biosciences Inc (NASDAQ:DARA) stock performance was -26.61% in last session and finished the day at $1.60. Traded volume was 4.15million shares in the last session and the average volume of the stock remained 501.39K shares. The beta of the stock remained 1.63. DARA Biosciences Inc (NASDAQ:DARA) insider ownership is 0.90%.

Analysts at Roth Capital assumed coverage on shares of Concert Pharmaceuticals Inc (NASDAQ:CNCE) in a research report issued to clients and investors on Thursday. The firm set a “buy” rating and a $28.00 price target on the stock. Roth Capital’s price objective suggests a potential upside of 224.07% from the stock’s previous close. Concert Pharmaceuticals Inc (NASDAQ:CNCE) rose 1.97 percent to $8.81 Thursday on volume of 115,127.00million shares. The intra-day range of the stock was $7.76 to $9.06. Concert Pharmaceuticals Inc (NASDAQ:CNCE) has a market capitalization of $157.70million.

Prosensa Holding N.V. (NASDAQ:RNA) announced that Luc Dochez, Chief Business Officer, will present a corporate overview at the Jefferies 2014 Global Healthcare Conference in New York, NY. The presentation is scheduled for Wednesday, June 4, at 1:30pm EDT. A live webcast of the presentation can be accessed through the Investors & Media section of the Prosensa corporate website at www.prosensa.com and will be archived for 90 days. Prosensa Holding NV (NASDAQ:RNA)’s stock on May 29, 2014 reported a increase of 11.67% to the closing price of $9.95. Its fifty two weeks range is $3.43 -$34.55. The total market capitalization recorded $357.95million. The overall volume in the last trading session was 967,517.00million shares. In its share capital, RNA has 35.90million outstanding shares.

CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, today announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS). On Thursday, shares of CytRx Corporation (NASDAQ:CYTR) dropped -5.33% to close the day at $3.91. Company return on investment (ROI) is -257.90% and its monthly performance is recorded as 24.52%. CytRx Corporation (NASDAQ:CYTR) quarterly revenue growth is -36.63%.